Seattle Genetics Stock News

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

After a barely discernible bottoming process, the rally has become obvious. Read more to see how I intend to take advantage of this rally.

Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 6 0 0 0 Last 30D 0 1

Morgan Stanley has decided to maintain its Overweight rating of Seagen (NASDAQ:SGEN) and lower its price target from $181.00 to $170.00. Shares of Seagen are trading up 0.36% over the last 24 hours, a

It's growing faster than competitors, but headwinds might soon bog it down.

It's growing faster than competitors, but headwinds might soon bog it down.

BMO Capital Markets upgraded Seagen Inc (NASDAQ: SGEN) from Market Perform to Outperform with a price target of $178 from $177, saying the core business is undervalued. BMO forecasts SGEN's commer

BMO Capital upgraded its rating of Seagen (NASDAQ:SGEN) to Outperform with a price target of $178.00, changing its price target from $177.00 to $178.00. Shares of Seagen are trading up 2.5% over the l

Upgrades According to Deutsche Bank, the prior rating for Scorpio Tankers Inc (NYSE:STNG) was changed from Sell to Hold. For the second quarter, Scorpio Tankers had an EPS of $3.13, compared to year-a

Learn more about an opportunity to acquire well-known big-cap names in the S&P 500 that, at this point, could provide "tech-like" returns.

Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down t

As it successfully transitioned into a commercial-stage operator, Seagen is enjoying great progress. The four drugs powering Seagen's marketed portfolio are generating robust revenue growth.

Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.